Issuance of Stock Options
First written in FY2018-Q3. 1 of 8 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2026.
- FY2026AchievedAnnual report
「The remaining unexercised rights expired on 13 March 2026 upon the end of the exercise period.」
Rights covering 32,800 shares under the 2020 stock options were exercised, while the remaining 8,300 shares expired when the exercise period ended. The exercise and expiration procedures for the 2020 grant have been completed. - FY2025-H1Stock option exercises continueAnnual report
「Proceeds from the exercise of stock options 16,601」
The Company recorded ¥16.601 million in proceeds from the exercise of stock options during the interim consolidated accounting period, and the remaining share acquisition rights continue to be exercised. - FY2024Forfeiture and partial exercise of the 2018 grantAnnual report
「The share acquisition rights issued pursuant to the Board of Directors' resolution of 16 January 2018 expired on 15 February 2024 upon the end of their exercise period.」
The unexercised portion of the 2018 stock options expired when the exercise period ended. During the fiscal year, rights covering 16,600 shares, including the 2019 and 2020 grants, were exercised, leaving share acquisition rights covering 73,700 shares from 2019 and 78,500 shares from 2020. - FY2022Partial exercise of stock optionsAnnual report
「Exercise of share acquisition rights 1,000」
The disclosure reports the exercise of rights covering 1,000 shares under existing stock options. - FY2021SoftenedAnnual report
「2020 stock options: 111,700 ordinary shares" "Unvested balance: 101,400 shares」
For the 2020 stock options, the Company disclosed the initial grant of 111,700 shares and the unvested balance of 101,400 shares after forfeitures, representing a reduction from the number of shares covered in the previous disclosure on an actual-results basis. - FY2020-Q3RaisedAnnual report
「Directors of the Company (excluding outside directors) 7 people 245 rights Employees of the Company, and directors (excluding outside directors) and employees of the Company's subsidiaries 93 people 955 rights The Company's ordinary shares: 120,000 shares (100 shares per share acquisition right) 5. Exercise period for the share acquisition rights From 14 March 2022 to 13 March 2026.」
At the Board of Directors meeting held on 16 January 2020, the Company resolved to issue share acquisition rights for 120,000 shares to directors, employees and officers and employees of subsidiaries. The number of shares covered increased from the previous 100,000 shares, and an exercise period was also established. - FY2019-Q3AdvancedAnnual report
「At the Board of Directors meeting held on 16 January 2019, the Company resolved as set out below regarding the issuance of new share acquisition rights as stock options, which had been approved at the 43rd Annual General Meeting of Shareholders held on 28 June 2018. "The Company's ordinary shares: 100,000 shares (100 shares per share acquisition right)" "Exercise period for the share acquisition rights: from 15 March 2021 to 14 March 2025"」
The Board of Directors resolved to issue share acquisition rights for 100,000 ordinary shares to directors, employees and officers and employees of subsidiaries, with an exercise period from 15 March 2021 to 14 March 2025. - FY2018-Q3First statedAnnual report
「The Company's common shares 100,000 shares (100 shares per share acquisition right)” “Directors of the Company (excluding outside directors) 7 people 205 rights” “Employees of the Company 50 people 555 rights” “Directors (excluding outside directors) and employees of the Company's subsidiaries 23 people 240 rights” “5. Exercise period of share acquisition rights From 16 February 2020 to 15 February 2024.」
At a meeting of the Board of Directors held on 16 January 2018, the Company resolved to issue share acquisition rights representing 100,000 shares for directors, employees, and officers and employees of subsidiaries. The exercise period is from 16 February 2020 to 15 February 2024.